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Abstract
Background: A high-quality programmed cell-death ligand 1 (PD-L1) diagnostic assay may help predict which
patients are more likely to respond to anti-programmed cell death-1 (PD-1)/PD-L1 antibody-based cancer therapy.
Here we describe a PD-L1 immunohistochemical (IHC) staining protocol developed by Ventana Medical Systems
Inc. and key analytical parameters of its use in formalin-fixed, paraffin-embedded (FFPE) samples of non-small cell
lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC).
Methods: An anti-human PD-L1 rabbit monoclonal antibody (SP263) was optimized for use with the VENTANA
OptiView DAB IHC Detection Kit on the automated VENTANA BenchMark ULTRA platform. The VENTANA PD-L1
(SP263) Assay was validated for use with FFPE NSCLC and HNSCC tissue samples in a series of studies addressing
sensitivity, specificity, robustness, and precision. Samples from a subset of 181 patients from a Phase 1/2 study of
durvalumab (NCT01693562) were analyzed to determine the optimal PD-L1 staining cut-off for enriching the
probability of responses to treatment. The scoring algorithm was defined using statistical analysis of clinical
response data from this clinical trial and PD-L1 staining parameters in HNSCC and NSCLC tissue. Inter-reader
agreement was established by three pathologists who evaluated 81 NSCLC and 100 HNSCC samples across the
range of PD-L1 expression levels.
Results: The VENTANA PD-L1 (SP263) Assay met all pre-defined acceptance criteria. For both cancer types, a cut-off
of 25 % of tumor cells with PD-L1 membrane staining of any intensity best discriminated responders from
nonresponders. Samples with staining above this value were deemed to have high PD-L1 expression, and those
with staining below it were deemed to have low or no PD-L1 expression. Inter-reader agreement on PD-L1 status
was 97 and 92 % for NSCLC and HNSCC, respectively.
Conclusions: These results highlight the robustness and reproducibility of the VENTANA PD-L1 (SP263) Assay and
support its suitability for use in the evaluation of NSCLC and HNSCC FFPE tumor samples using the devised ≥25 %
tumor cell staining cut-off in a clinical setting. The clinical utility of the PD-L1 diagnostic assay as a predictive
biomarker will be further validated in ongoing durvalumab studies.
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This article provides the full results of two abstracts that
have previously been presented and published [1, 2].
Background
Patients with recurrent and metastatic non-small cell
lung cancer (NSCLC) and head and neck squamous cell
carcinoma (HNSCC) have considerable unmet medical
needs and require improved treatments with the poten-
tial to provide prolonged survival and reduced exposure
to toxic chemotherapies [3–5].
It has long been recognized that the immune system is
capable of recognizing cancer as foreign and developing
a specific immune response. A number of stimulatory
and opposing inhibitory proteins have been shown to
regulate the quality and magnitude of the antitumor re-
sponse [6–9]. For example, tumors can evade detection
by the immune system by exploiting one or more of the
inhibitory (checkpoint) pathways that suppress antitu-
mor T-cell responses [9]. The therapeutic blockade of
these checkpoint molecules is actively being explored
across different cancers [6, 7]. One of the most promis-
ing approaches is antibody blockade of the programmed
cell death-1 (PD-1)/ programmed cell death ligand-1
(PD-L1) pathway [6, 7]. The anti-PD-1 agents nivolumab
and pembrolizumab have demonstrated clinical activity
across several tumor types and are now approved for
various indications worldwide [10–13]. While dramatic
responses have been seen in a number of patients
treated with anti-PD-1 and anti-PD-L1 antibodies, re-
sponses have typically represented only a fraction of
treated patients. This has led to a further search for bio-
markers predictive of response. Chief among these is the
demonstration of PD-L1 in tumor tissues using immu-
nohistochemistry (IHC). Two different IHC assays have
so far been approved by the Food and Drug Administra-
tion (FDA) for use as diagnostic tests in advanced
NSCLC; a complementary diagnostic for nivolumab [14]
and a companion diagnostic for pembrolizumab [15].
PD-L1 (B7-H1, CD274) is part of a complex system of
receptors and ligands that are involved in regulating T-
cell activation. Its main function is to regulate the bal-
ance between T-cell activation and tolerance through
interaction with its two receptors, PD-1 (CD279) and
CD80 (B7-1). In normal tissue, PD-L1 has been reported
to be expressed on a subset of T cells, B cells, dendritic
cells, macrophages, mesenchymal stem cells, and bone
marrow-derived mast cells, as well as various non-
hematopoietic cells [16, 17]. PD-L1 is expressed in a lim-
ited set of normal epithelial cells, such as placental
trophoblast cells and crypt epithelium of the tonsil [18].
Its expression in these locations is thought to provide
protection from cell-mediated attack. Importantly, and
in a similar fashion, PD-L1 is also expressed in a broad
range of carcinomas and other cancers [19–22] includ-
ing NSCLC and HNSCC [9, 16]. In the tumor micro-
environment, PD-L1 expressed on tumor cells binds to
PD-1 on activated T cells reaching the tumor. This
delivers an inhibitory signal to those T cells, preventing
them from killing target tumor cells, and protecting the
tumor from immune elimination [9].
PD-L1 biology is further complicated in additional ways.
For example, full-length PD-L1 is composed of an extra-
cellular domain that contains the PD-1 binding domain, a
shorter intracellular domain, and a short transmembrane
region. A number of antibodies to the extracellular and
intracellular domains have been generated and several of
those appear useful as IHC reagents [22–24]. It is also the
case that splice variants of PD-L1 have been identified [25,
26] and individual isoforms may localize to the cytoplasm
or membrane of cells in vitro. It should be noted, however,
that particular forms of the PD-L1 protein may be recog-
nized by some but not all of the other available antibodies.
Cytoplasmic or membrane immunolabeling of neoplastic
cells and macrophages have also been shown in tumor tis-
sues [19, 27]. PD-L1 localization to the cell membrane is
likely required for interaction with PD-1. In addition, PD-
L1 demonstrates a range of apparent expression levels in
cells, whether cytoplasmic or membranous. Tumor cells
or immune cells with variable intensities of PD-L1 expres-
sion could therefore suppress PD-1-expressing T lympho-
cytes to different degrees, although this has not yet been
proven. In addition to the biological heterogeneity of PD-
L1 expression (notably intra- and inter-tumoral and tem-
poral variations), [28, 29] there is also technical variability
due to a number of different assays (developed for diag-
nostic or research use) being used to label PD-L1 in tumor
tissue. These have variable target specificity and selectivity
(being raised to different epitopes on the PD-L1 mol-
ecule), and use different methods for antibody detection
and approaches to determining PD-L1 expression (scoring
systems and staining cut-offs) [28].
Not surprisingly then, given the various complexities
noted, substantial discordance is seen among published
studies relying on PD-L1 IHC [22–24]. Nonetheless, the
Rebelatto et al. Diagnostic Pathology  (2016) 11:95 Page 2 of 14
ability of a PD-L1 IHC method to account for those key
aspects of PD-L1 biology and tissue expression relevant
to therapy with either PD-1 or PD-L1 antibodies is ex-
pected to substantially contribute the overall usefulness
of the assay. In that context, for example, an assay that
demonstrates distinct cell membrane staining and a dy-
namic range of PD-L1 expression is highly desired. In
addition, the ability to optimally label PD-L1 on neoplas-
tic cells as well as immune cells is important, as is the
ability to perform across the range of tissue specimens
upon which the assay is expected to be applied. These
qualities are especially needed to increase the ability to
accurately identify patients who may respond to im-
munotherapies targeting PD-L1 or PD-1. At the same
time, they contribute to a more comprehensive and po-
tentially accurate assessment of PD-L1 that reflects the
complexities of its expression in a range of tumor types
and that may be required to clarify aspects of its im-
munosuppressive role in cancer that are not yet fully
understood.
Durvalumab (MEDI4736) is a selective, high-affinity
human IgG1 monoclonal antibody that blocks PD-L1
binding to PD-1 and CD80 but does not bind to pro-
grammed cell death ligand-2 (PD-L2) [30]. PD-L2 plays
a role in controlling inflammation in normal lung tissue
(with expression in lung macrophages and antigen-
presenting cells) [31] and this may help to avoid PD-L2-
mediated immune-related toxicities, which have been
observed in animal models [32, 33]. In an ongoing Phase
1/2 study of patients with advanced solid tumors, durva-
lumab monotherapy has demonstrated a manageable tol-
erability profile and encouraging antitumor activity
across multiple tumor types, including NSCLC and
HNSCC [34, 35].
Most NSCLC tumors do not express PD-L1 at high
levels, although reported levels vary; [20, 36, 37] only
~20 % of NSCLC tumors were reported to show PD-L1
expression in 5 % or more of tumor cells obtained with
three different IHC assays (using different PD-L1 anti-
body clones; E1L3N, 22C3, and 5H1) [20, 38, 39]. In
HNSCC, tissue PD-L1 immunostaining increases vs.
normal controls [27] with variable levels of PD-L1 ex-
pression [18, 35, 40]. The absence of detectable PD-L1
in some tumors may account for poor responses to anti-
PD-1/PD-L1 therapy. A sensitivity analysis of the clinical
activity of nivolumab, pembrolizumab, and the anti-PD-
L1 agent atezolizumab in NSCLC [41–48] demonstrated
that overall response rates were significantly lower in pa-
tients with PD-L1 low tumors (1–5 % tumor cells
stained using various PD-L1 assays) than in patients with
PD-L1 high tumors [42]. Evidence from some individual
clinical studies of the anti-PD-1/PD-L1 agents nivolu-
mab, durvalumab, pembrolizumab, atezolizumab, and
avelumab also suggest that patients with PD-L1 high
tumors can experience improved treatment benefits vs.
those with PD-L1 low tumors [34, 43, 47, 49, 50].
The development and application of diagnostic tests in
clinical practice to identify patients most likely to benefit
from anti-PD-1/PD-L1 therapy could improve patient
outcomes and decrease healthcare costs, while directing
patients that are less likely to respond towards other al-
ternative treatment options. Research into the relative
performance of different PD-L1 assays and their reliabil-
ity for detecting PD-L1 is ongoing [51]. These diagnostic
tests, which are designed to aid treatment decisions with
specific anti-PD-1 therapies [23, 29, 52], are likely to be
among the key drivers for the future of personalized
health care in oncology [23].
In this paper, we describe the development and valid-
ation of the VENTANA PD-L1 (SP263) Assay (PD-L1
[SP263]) (Ventana Medical Systems Inc., Tucson, AZ,
USA), which has been designed for the detection of PD-
L1 protein in formalin-fixed, paraffin-embedded (FFPE)
NSCLC and HNSCC tumor samples. In addition, we de-
scribe the identification and validation of scoring criteria
(defined with tissues from a durvalumab clinical trial)
that can be used to classify samples as PD-L1 high ex-





The PD-L1 (SP263) assay uses an anti-human PD-L1
rabbit monoclonal antibody (SP263) directed against the
cytoplasmic region of human PD-L1. This peptide was
synthesized and conjugated to the carrier protein key-
hole limpet hemocyanin. New Zealand White rabbits
were immunized with keyhole limpet hemocyanin conju-
gated peptide emulsified with complete Freund’s adju-
vant followed by a series of booster doses of immunogen
emulsified with incomplete Freund’s adjuvant. The rabbit
that generated IHC-positive polyclonal antibody was
then selected for monoclonal antibody development
using Spring Bioscience’s proprietary technology.
Briefly, antibody-expressing cells were isolated and
screened by enzyme-linked immunoabsorbent assay
for reactivity to the immunogen and by IHC on con-
trol tissue blocks. Complementary DNA coding for
antibody heavy chains and light chains was isolated
from IHC-positive clones. Monoclonal antibodies were
produced by co-transfection of heavy- and light-chain
complementary DNA and tested again by IHC. The
clone producing antibodies with the best specificity
was selected. A larger transfected production lot was
produced and the monoclonal antibody was purified
through a Protein A column.
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Staining protocol
The antibody was designed to be used in conjunction
with the VENTANA OptiView diaminobenzidine tetra-
hydrochloride (DAB) IHC Detection Kit (P/N 760-700)
and the staining protocol for the assay is provided in
Table 1. This protocol represents the selectable options
within the detection kit procedure. The OptiView DAB
IHC Detection Kit is an indirect, biotin-free system for
detecting mouse IgG, mouse IgM, and rabbit primary
antibodies used to detect target antigens in FFPE tissue,
The 3-hydroxy-2-quinoxalinecarbamide (hydroxyqui-
noxaline) universal linker conjugated with hydroxyqui-
noxaline haptens binds to the primary antibody and is
recognized by the horse radish peroxidase multimer.
The remaining components in the detection kit func-
tion to create a brown 3,3’-DAB precipitate on the
tissue section at the site of PD-L1 antigen.
Normal-term placenta can be used as a positive and
negative tissue control for the assay. Tissue controls
were used to monitor the correct performance of proc-
essed tissues, test reagents, and instruments. One pla-
centa control was included on each staining run.
Cell line analysis of PD-L1 expression
The SP263 antibody was tested by immunocytochem-
istry on the following cell lines: Calu-3, KARPASS 299,
H820, H1975, MDA-MB231, T-47D, LOX, ACHN,
MCF-7, and HCT-116. In addition, HEK293 cell lines
transfected to express varying levels of PD-L1 were pre-
pared to test PD-L1 expression across the dynamic range
and were also transfected to express PD-L2 to demon-
strate antibody specificity.
Flow cytometry analysis
Tumor cell lines (LOX, MCF-7, MDA-MB231, HCT116,
and ACHN) were evaluated for surface PD-L1 expres-
sion and the number of receptors per cell was estimated
using flow cytometry. Briefly, tumor cell suspensions
were incubated with 100 μl of anti-human PD-L1 anti-
body (R&D systems, catalog MAB1561) diluted in flow
cytometry analysis (FACS) buffer (phosphate-buffered
saline plus 2 % heat inactivated fetal bovine serum) for
45 min at 4 °C. After primary monoclonal antibody incuba-
tion, cells were washed with cold FACS buffer and resus-
pended in 100 μl QIFI Kit FITC secondary antibody diluted
1:50 with FACS buffer (Dako QIFI Kit, catalog #K0078, lot
00088291). Secondary detection antibody incubation was
conducted for 45 min at 4 °C, protected from light. After
secondary incubation, cells were washed once with cold
FACS buffer and resuspended in FACS buffer for flow cyto-
metric analysis performed on a BD LSR II Flow Cytometer
(BD Biosciences, Mountain View, CA, USA). Using the
setup provided in the QIFI kit, a standard curve was plotted
using the mean fluorescent intensity values and calculated
using GraphPad Prism 6 software. The x values were deter-
mined, which correlated to the number of receptors per cell.
Western blot analyses of cell lysates
Western blot studies were conducted by SDS-PAGE.
Cell lysates were prepared from four different cell lines
that demonstrated varying IHC protein expression
(H820, MDA-MB231, H1975, and Calu-3 cell lines). A
recombinant human PD-L1 protein served as a positive
control and a recombinant BCL-2 protein served as a
negative control for the study. An anti-actin antibody
(8H10D10) (Cell Signaling Technologies, Danvers, MA,
USA) was used to detect a ~42 kD protein actin. This
constitutively expressed reference protein ensured
equivalent loading of samples onto the gel.
Staining of commercially available normal and tumor tissue
samples
Normal and tumor tissue array samples (Tissue Micro-
array FDA808ci, US Biomax, Rockville, MD, USA) were
stained with the PD-L1 (SP263) rabbit monoclonal anti-
body using the final optimized protocol on the Bench-
Mark ULTRA. A rabbit monoclonal negative-control Ig
was also analyzed for the array staining run.
Evaluation of PD-L1 staining on tumor samples
All tumor sample evaluations were conducted by board-
certified pathologists at Ventana’s College of American
Pathologists accredited and Clinical Laboratory Im-
provement Act certified laboratory. Upon receipt of each
sample, hematoxylin and eosin staining was performed
to determine the number of tumor cells. The sample
was considered acceptable for further analysis if it con-
tained ≥100 viable tumor cells. The PD-L1 (SP263) assay
was carried out on 4–6 μm sample sections mounted
onto positively charged slides. PD-L1 staining was evalu-
ated by estimating the percentage of cells stained at
Table 1 Recommended staining protocol for VENTANA PD-L1




Cell conditioning (Antigen unmasking) Cell conditioning 1, 64 min
Pre-primary peroxidase inhibitor Selected
Antibody (primary) 16 min, 36 °C
OptiView HQ linker 8 min (default)
OptiView HRP multimer 8 min (default)
Counterstain Hematoxylin II, 4 min
Post counterstain Bluing, 4 min
DAB 3, 3’-diaminobenzidine tetrahydrochloride, HRP horse radish peroxidase,
HQ hydroxyquinoxaline, IHC immunohistochemistry, PD-L1 programmed cell
death ligand-1
Rebelatto et al. Diagnostic Pathology  (2016) 11:95 Page 4 of 14
different intensities, from 0 to 3, with 0 representing no
staining and 3 representing strong staining. This per-
centage was determined for staining localized in the
cytoplasm and membrane of tumor cells. In addition,
PD-L1 staining in tumor-associated immune cells (mac-
rophages, dendritic cells, lymphocytes, etc.) was evalu-
ated as a percentage of immune cells present in the
tumor area.
PD-L1 scoring algorithm: Statistical analysis to identify the
cut-off for determining PD-L1 positive/negative tumors
In NSCLC and HNSCC samples, PD-L1 was generally
expressed as a continuum, ranging from a few tumor
cells and/or immune cells expressing PD-L1 to the ma-
jority of tumor cells and immune cells expressing the
target. Intensity of staining also varied, with mixtures of
weak, moderate and intensely-stained tumor, and im-
mune cells sometimes seen in single tumor specimens.
To understand the association of the biomarker with
clinical response, patient samples need to be classified
into categories. For these purposes, samples were classi-
fied into two categories: high and low/no expression.
The optimal scoring criteria were determined by Max-
imal Chi-square [53] and receiver operating characteris-
tic (ROC) curves [54] of the PD-L1 staining parameters
relative to clinical response in a subset of 155 patients
with NSCLC enrolled in the NCT01693562 clinical trial
[1, 34, 35]. The cut-off determination for the PD-L1
(SP263) assay was made following retrospective evalu-
ation of their tumor samples as well as commercially
available tumor samples. The considerations for the se-
lected cut-off included prevalence, clinical outcome and
the reproducibility of the test.
The endpoints used for the actual cut-off determin-
ation were the confirmed objective response (Y) per
RECIST v1.1 based on investigator assessment and the
percentage tumor cell membrane positivity for PD-L1
(X).
This scoring algorithm and the selected cut-off were
utilized in the definitions of PD-L1 high and PD-L1 low/
negative in the subsequent verification studies.
PD-L1 (SP263) assay verification studies
Cut-slide stability
Cut-slide stability was evaluated on four tissue samples
stained with the recommended assay protocol after
storage under two different conditions (2–8 and 30 °C).
Cut-slide stability was also assessed on slides stained at
various timepoints after sectioning. Slides sectioned and
stained at the Day 0 timepoint served as the comparator
for the remainder of the tested timepoints (Day 3, 14,
and monthly from Month 1–12 for NSCLC and Day 3,
14, and monthly from Month 1–10 for HNSCC).
Tissue thickness
Tissues were sectioned at various thicknesses (3–7 μm)
to assess the effect of thickness on the staining perform-
ance of the PD-L1 (SP263) assay. The placenta tissue
positive-control slides included in the staining run were
sectioned at 4 μm. Slides were required to stain within
1.0 intensity point of each other and to maintain the
same PD-L1 status (high or low/no expression).
Fixation type and time and ischemia
The effects of fixative type and fixation time were evalu-
ated in tonsil-positive control tissue. Tonsil cases were
processed in six fixatives (10 % neutral-buffered formalin
[NBF], zinc formalin, 95 % alcohol, acidified formal alco-
hol (AFA), Z5 and Prefer) with multiple timepoints (1, 6,
12, 24, 72 h) in each fixative. The effects of ischemia
were also investigated using KARPASS 299 xenograph
tissues with ischemic times varying between 0, 0.5, 1, 2,
6, and 24 h. The immunostained slides were read and
scored by a board-certified pathologist on a 0–3 inten-
sity scale for specific PD-L1 staining and background.
Data were then compared to the reference standard
(10 % NBF for 24 h).
Intermediate precision
This design verification study was conducted to assess
the PD-L1 (SP263) assay’s staining precision in NSCLC
and HNSCC. Samples included both PD-L1 high and
PD-L1 low/negative tissues across i) three different PD-
L1 (SP263) antibody lots; ii) three OptiView DAB IHC
Detection Kit lots; and iii) three BenchMark ULTRA
instruments. This study was designed to verify the inter-
mediate staining precision (inter-antibody lot, inter-
detection kit lot, and intra-platform) of the PD-L1
(SP263) assay. A total of nine PD-L1 high and nine PD-
L1 low/negative samples for each tumor type, spanning
the range of PD-L1 expression, were used in the study.
Intra-day (slide to slide) precision
A total of 10 NSCLC and 10 HNSCC whole tissue sam-
ples (comprising five PD-L1 high and five PD-L1 low/
negative samples for each tumor type) spanning the
range of PD-L1 staining were evaluated across a cohort,
which represented the dynamic range of PD-L1 expres-
sion. For intra-day repeatability, five replicate slides from
each of the NSCLC or HNSCC specimens were stained
on a single BenchMark ULTRA instrument (Tucson,
AZ, USA) across two staining runs for NSCLC and
HNSCC, respectively.
Intra-platform precision
A total of 10 NSCLC and 10 HNSCC samples (comprising
five PD-L1 high and five PD-L1 low/negative samples for
each tumor type) spanning the range of PD-L1 expression
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were evaluated across three BenchMark ULTRA instru-
ments. Three staining runs were conducted for NSCLC
and HNSCC, respectively.
Inter-day (day-to-day) precision
A total of 10 NSCLC and 10 HNSCC whole tissue sam-
ples (comprising five PD-L1 high and five PD-L1 low/
negative cases for each tumor type) spanning the range
of PD-L1 expression were evaluated. Two replicate slides
were stained for each sample on three BenchMark
ULTRA instruments on five non-consecutive days over a
minimum span of 20 days.
Inter-laboratory precision
A total of 14 NSCLC and 14 HNSCC whole tissue sam-
ples (comprising seven PD-L1 high and seven PD-L1
low/negative cases for each tumor type) were evaluated.
Cases were selected to cover the range of expression and
included borderline cases around the cut-off. Each case
was stained five different times in each laboratory. Three
different laboratories were assessed. Two pathologists
per laboratory conducted the scoring.
Reader verification of the scoring algorithm – inter- and
intra-reader agreement
Between-reader (inter-reader) agreement with the PD-L1
(SP263) assay scoring algorithm was determined using a
cohort of NSCLC tissue samples (previously screened
for PD-L1 status) obtained from commercial sources
and stained using the PD-L1 (SP263) assay. A total of 81
NSCLC samples (40 PD-L1 high and 41 PD-L1 low/
negative) together with 100 HNSCC samples (50 PD-L1
high and 50 PD-L1 low/negative) were evaluated across
the dynamic range of staining. Three readers were
trained on the scoring algorithm and provided with the
blinded and randomized study samples for scoring.
Readers completed the initial scoring within 2 weeks
and the scores were analyzed. There was a mandatory 2-
week break period prior to the intra-reader precision
scoring. Slides were then re-randomized and provided to
the readers for intra-reader scoring.
Results
Antibody sensitivity and specificity
The SP263 antibody showed a high degree of sensitivity
and specificity for PD-L1 in cell lines with various levels
of PD-L1 expression, as determined by flow cytometry,
immunocytochemistry (Fig. 1), and Western blot analysis
(Fig. 2). The IHC protocol demonstrated a wide dynamic
range, as indicated by intensities of staining of cell lines
appropriate to their varying levels of PD-L1 expression.
As Fig. 1 illustrates, immunolabeling ranged from min-
imal or mild in HCT116 (very low expression, ~1,600
molecules per cell) and ACHN cells, to moderate in
MDA-MB231 cells, to intense in LOX (high expres-
sion, ~15,000 receptors per cell).
Western blot analysis of cell lysates
A single band of the appropriate molecular weight of
fully glycosylated PD-L1 (~55 kDa) was detected by
Fig. 1 PD-L1 expression in adenocarcinoma cell lines labeled with the PD-L1 (SP263) antibody. Cell staining and flow cytometry results. Photomi-
crographs of cell lines stained with the PD-L1 (SP263) antibody (20X): MCF7 (negative control, no PD-L1 staining), HCT116 (low level of PD-L1
staining), ACHN (medium PD-L1 staining), MDA-MB231 (high-level PD-L1 staining), LOX (high-level PD-L1 staining). Corresponding fluorescence
intensities achieved by flow cytometry with the same cell lines labeled with the PD-L1 (SP263) antibody. Ctrl control, PD-L1 programmed cell
death ligand-1
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Western blot in the H820, MDA-MB231, and H1975 cell
lines using the PD-L1 (SP263) antibody (Fig. 2). No band
was detected for the Calu-3 negative-control cells. These
results demonstrated the high specificity of SP263 for
PD-L1.
Additional cell lines were examined using immuno-
cytochemistry to further evaluate the specificity and sen-
sitivity of the PD-L1 (SP263) assay for the PD-L1
analyte. In cell lines with differential native PD-L1-
specific expression, PD-L1 staining intensity with the
IHC assay corresponded to the relative levels of PD-L1
expression (LOX > ~MDA-MB231 > ACHN >HCT116 >
MCF-7) (Fig. 1 and Table 2). In addition, human embry-
onic kidney cells (HEK293) were transfected to express
varying levels of PD-L1 and examined for PD-L1 reactiv-
ity. HEK cells containing empty vector showed no
immunolabeling, whereas the transfected HEK cell lines
displayed differential PD-L1-specific labeling appropriate
to their protein expression levels. The HEK293 cells
transfected to express the closely-related PD-L2 protein
had no detectable immunostaining by the PD-L1
(SP263) assay (Table 2).
Staining of commercially available normal and tumor tissue
arrays
The PD-L1 immunostaining features of SP263 were
further examined in a panel of normal human tissues,
where staining was notable particularly in lymph
node, tonsil, stomach (typically chief, or zymogenic
cells), and placenta. As tonsil and lymph node are
known to contain immune cells expressing PD-L1,
staining in these tissues was expected. Trophoblast-
lineage cell staining in placenta was also anticipated.
No specific PD-L1 staining was observed in the par-
enchyma of a single normal lung core.
The following tumor tissue samples stained using the
SP263 assay demonstrated PD-L1 immunostaining of
tumor cells: squamous cell carcinoma of the skin, infil-
trating ductal carcinoma of the breast, cholangiocarci-
noma of the liver, Hodgkin lymphoma, squamous cell
carcinoma of the lung, gastric adenocarcinoma, diffuse
large B-cell lymphoma (in stomach), squamous cell car-
cinoma of the uterine cervix, endometrial adenocarcin-
oma, and thyroid papillary carcinoma. Most specimens
also demonstrated immunostaining of tumor-infiltrating
immune cells. The degree of apparent background stain-
ing was reported as ≤0.5 (faint) intensity on all evaluated
cores, a level that generally did not interfere with
specific PD-L1 labeling and therefore was judged to
be acceptable. Additional commercial samples of
NSCLC and HNSCC tissue showed similar PD-L1 la-
beling in a number of tumors. Figure 3 illustrates the
range of SP263 staining intensities and frequencies in
these tumors.
Fig. 2 Western blot analyses of cell lysates labeled with the PD-L1 (SP263) antibody. Western blot analysis of cell lysates from adenocarcinoma
cell lines loaded onto an SDS-PAGE gel and labeled with the PD-L1 (SP263) antibody. The antibody labeled a single band of the appropriate
molecular weight for fully glycosylated PD-L1 (~55 kDa). Relative levels of PD-L1 immunoreactivity matched the known relative PD-L1 mRNA
expression levels for these cell lines (H820 >MDA-MB231 > H1975 > Calu-3). PD-L1 programmed cell death ligand-1
Table 2 Cell lines with differential PD-L1 expression stained
with the PD-L1 (SP263) antibody
Membrane Cytoplasm




MCF-7 0 NA 0 NA
HCT116 5 1.25 5 0.75
ACHN 50 1 0 NA
LOX 95 2.5 85 1.5
MDA-MB231 100 2.25 90 0.75
HEK293-vector 0 NA 0 NA
HEK293−
PD-L1+
5 3 5 3
HEK293−
PD-L1++
15 2.75 15 2.75
HEK293−
PD-L1+++
20 2.75 20 2.75
HEK293−
PD-L2+++
0 0 0 0
NA not applicable, PD-L1 programmed cell death ligand-1, PD-L2 programmed
cell death ligand-2
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PD-L1 scoring algorithm
Clinical response to durvalumab and PD-L1 expres-
sion in tumor biopsies correlated best with PD-L1
expression in tumor cells rather than immune cells.
In a subset of 155 patients with NSCLC in the Phase
1/2 trial, the optimal cut-off identified statistically
(Fig. 4) was 38 %. However, based on other consider-
ations (e.g., prevalence in the population, ease of
scoring by pathologists, optimizing for higher nega-
tive predictive value), a cut-off of 25 % of tumor
cells with membrane staining for PD-L1 at any in-
tensity level above background was selected for the
verification studies. Logistic regression showed a sig-
nificant relationship between tumor membrane stain-
ing score and probability of response (p-value =
0.0003, Fig. 5). Separate analysis of HNSCC samples
from this study independently confirmed the reliabil-
ity of the ≥25 % staining cut-off and exclusion of
cytoplasmic tumor cell staining, immune cell stain-
ing, and staining intensity from the analysis of PD-
L1 staining expression (data not shown).
PD-L1 (SP263) assay verification study results
Cut-slide stability
The staining performance on NSCLC and HNSCC tis-
sues stored at 2–8 and 30 °C passed the acceptance cri-
teria. This test also demonstrated that staining at the
Day 3 and 14, and Months 1–13 timepoints was consist-
ent with results obtained on Day 0 for NSCLC tissues
and staining at the Day 3 and 14, and Months 1–10
timepoints was consistent with results obtained on Day





Fig. 3 PD-L1 (SP263) antibody staining in tumor tissue samples. Photomicrographs of PD-L1 (SP263) staining in NSCLC and HNSCC tissue, demon-
strating the range of PD-L1 staining intensity and frequency obtained with the PD-L1 (SP263) assay on NSCLC (a-d) and HNSCC (e-h) samples. a,
e negative tumor cells (20X), positive immune cells; b, f (10X): low tumor staining; c, g (10X): moderate tumor staining; d, h (10X,20X): high tumor
staining. HNSCC head and neck squamous cell carcinoma, NSCLC non-small cell lung cancer, PD-L1 programmed cell death ligand-1
Fig. 4 ROC analysis on confirmed objective response (per RECIST v1.1 per investigator). Analysis provided the rationale for the choice of tumor
membrane score and 25 % cut-off. AUC area under the curve, NSCLC non-small cell lung cancer, RECIST Response Evaluation Criteria In Solid
Tumors, ROC receiver operating characteristic, TM tumor membrane
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Tissue thickness and ischemia
Appropriate antibody staining was achieved across all
tissue section thicknesses tested (3, 4, 5, 6, and 7 μm)
(Table 3), which was consistent with PD-L1 high or
low/negative outcomes for each case evaluated for
both NSCLC and HNSCC. Variations in the types of
tissue fixative used (either 10 % NBF, zinc formalin,
or Z5) over time periods ranging from 6 to 72 h and
cold tissue ischemia for periods ranging from 0 to 24
h also had a negligible effect on staining performance
achieved with the PD-L1 (SP263) assay (Table 3).
Fixation with 95 % alcohol, AFA and Prefer are not
recommended for use with the assay as they caused a
loss of staining intensity for PD-L1.
Intra-day (slide to slide) precision, intra-platform precision,
and inter-day (day-to-day) precision
The intra-day reproducibility of the PD-L1 (SP263)
assay within a single staining run exceeded the 90 %
pass criterion set for this study; overall percentage
agreement (OPA) for PD-L1 high vs. low/no expres-
sion was 100.0 % with a 95 % confidence interval
(CI) of 92.9–100.0. The positive percentage agree-
ment was 100.0 % (95 % CI: 88.6–100.0) and the
negative percentage agreement was 100.0 % (95 %
CI: 83.9–100.0). The assay also exceeded the 90 %
pass criteria set for intra-platform precision (per-
formance across three BenchMark ULTRA instru-
ments) and inter-day precision (performance on the
same BenchMark ULTRA instrument over 5 non-
consecutive days for a minimum of 20 days)
(Table 4). All the tissues tested in these assay per-
formance studies had acceptable background stain-
ing, which did not interfere with interpretation of
PD-L1 high vs. low/negative results. Inter-lot vari-
ability of either antibody or DAB visualization re-
agents also had a negligible effect on assay
performance (Table 4).
Fig. 5 Relationship between ORR (per RECIST v1.1 per investigator) and tumor membrane score (logistic regression). *Based on N = 155 NSCLC
patients enrolled prior to enrichment. CI confidence interval, NSCLC non-small cell lung cancer, ORR objective response rate, RECIST Response
Evaluation Criteria In Solid Tumors
Table 3 Preanalytic factors
Study outline Design Results
Tissue thickness NSCLC and HNSCC tissues sectioned at various
thicknesses (3, 4, 5, 6, and 7 μm)
Antibody demonstrated appropriate staining across
all thicknesses tested and was representative of
clinical PD-L1 status for each case
Tissue fixation Tonsil cases processed in 10 % NBF,
zinc formalin, 95 % alcohol, AFA,
Z5 and Prefer with multiple timepoints
(1, 6, 12, 24, and 72 h) in each fixative
Timepoints (6, 12, 24, and 72 h) in 10 % NBF,
zinc formalin and Z5 were acceptable; 95 % alcohol,
AFA and Prefer were not acceptable
Ischemia KARPASS 299 xenograft tissues with
multiple cold ischemia times
(0, 0.5, 1, 2, 6, and 24 h)
No significant change in staining intensity from
time 0 to hour 24
Cut-slide stability Four tissue samples; cut at 4 μm and
stored at 2–8 and 30 °C. Stained at the
Day 0 timepoint and at Day 3 and 14
and monthly Month 1 to 12 timepoints
Staining results at different storage temperatures
and at timepoints Day 3 and 14, and Months 1 to
12 consistent with results achieved on Day 0
AFA acidified formal alcohol, HNSCC head and neck squamous cell carcinoma, NBF neutral buffered formalin, NSCLC non-small cell lung cancer, PD-L1 programmed cell
death ligand-1
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Intermediate precision (inter-antibody lot, inter-detection kit
lot, and intra-platform)
The intermediate precision design verification study
was conducted to assess PD-L1 (SP263) assay staining
precision on NSCLC tissues representing the clinical
status range. The antibody exceeded the 90 % pass
criteria set across the three antibody lots, three detec-
tion kit lots and three BenchMark ULTRA platforms
(Table 4). All the tissues tested in these assay per-
formance studies had acceptable background staining,
which did not interfere with interpretation of PD-L1
high vs. low/negative results.
Intra-reader and inter-reader precision (agreement)
For NSCLC, the OPA between the three readers was
96.7 %. The average positive agreement (APA) and
average negative agreement (ANA) between the three
readers was 96.6 and 96.8 %, respectively (Table 5).
The intra-reader (within reader) OPA was 96.3 %, the
APA was 96.2 % and the ANA was 96.4 %. For
HNSCC, the OPA between the three readers was
90.8 %. The APA and ANA between the three readers
was 90.9 and 90.8 %, respectively. The intra-reader
OPA was 94.3 %, the APA was 94.4 %, and the ANA
was 94.3 %. These results met the requirement cri-
teria for the assay.
Inter-laboratory reproducibility
For NSCLC, the average positive and average negative
inter-laboratory reproducibility was 93.3 % and 79.5 %,
respectively. The OPA was 86.4 %. For HNSCC, the
average positive and average negative inter-laboratory re-
producibility was 89.4 and 99.5 %, respectively. The OPA
was 94.5 % (Table 6). These results met the requirement
criteria for the assay.
Discussion
IHC assays used to detect the presence of PD-L1 protein
in tumor tissues are designed and needed to aid clinical
treatment decisions by identifying cancer patients most
likely to respond to antibody therapies that target the
PD-1/PD-L1 pathway. This must be considered in the
context that PD-L1 expression is complicated in a num-
ber of ways, as previously noted. Chief among these are
that PD-L1 protein may localize to the cytoplasm or cell
membrane, [19, 27] expression levels vary greatly among
individual cells, [28, 29] and PD-L1 is expressed in
tumor cells of a number of important cancer types as
well as immune cells in even more cancers. In particular,
PD-L1 expression is characteristic of a number of
NSCLC [20, 38, 39] and HNSCC patients [18, 35, 40]. In
this light, the VENTANA PD-L1 (SP263) Assay was de-
veloped to address many of these complexities and was
validated to reliably detect PD-L1 protein in FFPE
NSCLC and HNSCC tissue samples using a rabbit
monoclonal antibody optimized for use with the Opti-
View DAB IHC Detection Kit.
The PD-L1 (SP263) assay showed the required level of
analytical specificity and sensitivity for detecting
Table 4 PD-L1 (SP263) assay performance test results
Study outline Design NSCLC results, %
(95 % CI)
Intra-day: performance











on the same BenchMark
ULTRA instrument over
5 non-consecutive days














PPA & NPA n = 243










PPA & NPA n = 243
















CI confidence interval, NPA negative percentage agreement, NSCLC non-small
cell lung cancer, OPA overall percentage agreement, PD-L1 programmed cell
death ligand-1, PPA positive percentage agreement
Table 5 Inter- and intra-reader performance results




NSCLC cases: inter- and intra-reader
agreement on a cohort previously




APA 96.6 % (93.8–98.8)
ANA 96.8 % (93.9–98.9)
OPA 96.7 % (94.2–98.9)
APA 96.2 % (92.7–98.8)
ANA 96.4 % (93.0–98.8)
OPA 96.3 % (93.3–98.8)
HNSCC cases: inter- and intra- reader
agreement on a cohort previously




APA 90.9 % (86.0–94.9)
ANA 90.8 % (86.0–94.8)
OPA 90.8 % (86.7–94.7)
APA 94.4 % (91.1–97.1)
ANA 94.3 % (91.0–97.1)
OPA 94.3 % (91.3–97.0)
ANA average negative agreement, APA average positive agreement, CI confidence interval, HNSCC head and neck squamous cell carcinoma, NSCLC non-small cell
lung cancer, OPA overall percentage agreement, PD-L1 programmed cell death ligand-1
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engineered and endogenous PD-L1 protein in cell lines
across a wide dynamic range of expression. Additionally,
it was shown to detect PD-L1 expression levels as low
as ~1,600 receptors per cell. The rabbit monoclonal
antibody used in the assay was raised against the cyto-
plasmic region of human PD-L1 and produced a single
clear band of the appropriate molecular weight in
Western blot analysis. Target specificity was also dem-
onstrated by transfecting PD-L1 into cell lines with no
endogenous PD-L1 expression, producing clear stain-
ing with the PD-L1 (SP263) assay, and no staining in
cells transfected with PD-L2. Antibodies raised against
the cytoplasmic domain of PD-L1 have been reported
to offer better visualization of membrane PD-L1 com-
pared with those raised against the extracellular do-
main [22].
The assay detected PD-L1 immunoreactivity with the
anticipated staining patterns in a panel of normal tissue
samples with known PD-L1 expression (e.g., placental
trophoblasts and immune cells) and in tumor cells from
NSCLC and HNSCC tissue samples with a range of PD-
L1 staining intensities and frequencies representing the
heterogeneity of tissue expression. No unexpected cross-
reactivity was observed with the antibody.
Numerous analytical variables have the potential to
affect the reliability of assay results and the impact of
these variables was extensively evaluated during assay
development. In terms of preanalytical variables, the
antibody demonstrated appropriate staining across all
tissue section thicknesses tested and also accurately rep-
resented the PD-L1 high or PD-L1 low/negative staining
status in each case. Changes in the recommended tissue
fixative used (10 % NBF, zinc formalin, or Z5 [95 % alco-
hol, AFA, and Prefer not recommended]) over time pe-
riods ranging from 6 to 72 h and cold tissue ischemia
for periods ranging from 0 to 24 h had a negligible effect
on staining performance, as did cut-slide storage condi-
tions of 2 − 8 and 30 °C for varying time periods of up to
12 months.
For assay performance over repeated measurements,
the assay exceeded the 90 % pass criterion for intra-day
reproducibility within a single staining run, inter-day
precision (performance on the same BenchMark ULTRA
instrument over 5 non-consecutive days for a minimum
of 20 days) and intra-platform precision (performance
across three BenchMark ULTRA instruments). The assay
also exceeded the 90 % pass criteria for determination of
intermediate precision across three antibody lots, three
detection kit lots, and three BenchMark ULTRA plat-
forms. Assay performance test scores (negative percent-
age agreement, positive percentage agreement, and
OPA) were in the same range as those reported for the
FDA-approved Dako PD-L1 IHC 28-8 pharmDx and
PD-L1 IHC 22C3 pharmDx assays [14, 15]. Inter- and
intra-reader performance scores (APA, ANA, and OPA)
were all >90 % and comparable with observer-to-
observer reproducibility values reported for the validated
Dako PD-L1 IHC 28-8 pharmDx [52] and PD-L1 IHC
22C3 pharmDx assays [15].
A scoring algorithm for PD-L1 staining with the PD-
L1 (SP263) assay was defined on the basis of an analysis
of PD-L1 staining parameters observed from NSCLC
and HNSCC samples from the NCT01693562 clinical
trial of durvalumab, together with clinical response data.
Statistical analysis of PD-L1 staining parameters in this
study indicated that the parameter that correlated best
with clinical response to durvalumab was PD-L1 expres-
sion in the membrane of tumor cells, regardless of stain-
ing intensity. Other PD-L1 parameters, however, remain
under investigation. Samples were considered to have
high expression when ≥25 % of viable tumor cells dem-
onstrated membrane staining for PD-L1 at any intensity
[1]. The scoring algorithm thus separates patients into
two groups: PD-L1 high (≥25 % of tumor cells with
membrane staining for PD-L1), and PD-L1 low/negative
(<25 % of tumor cells with membrane staining). Separate
analysis of samples from NSCLC and HNSCC cohorts
independently confirmed the reliability of the ≥25 %
staining cut-off and exclusion of cytoplasmic tumor cell
staining, immune cell staining, and staining intensity
from the analysis of PD-L1 staining status. Using this de-
fined scoring algorithm, the classifications of patient
tumor samples as PD-L1 high or PD-L1 low/negative
were highly reproducible among pathologists, with an
OPA of 96.7 % for NSCLC among three pathologists.
Although several different assays to determine PD-L1
positivity in tumor tissue have been developed, few have
been performance tested using comparable assay condi-
tions. There may be differences in assay performance
owing to the diversity of antibody clones with different
Table 6 Inter-laboratory performance results
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HNSCC head and neck squamous cell carcinoma, NPA negative percentage
agreement, NSCLC non-small cell lung cancer, OPA overall percentage agree-
ment, PPA positive percentage agreement
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affinities, raised against different areas (epitopes) on the
PD-L1 molecule (e.g., clones E1L3N, SP142, and SP263
are raised to epitopes within the intracellular domain,
and clones 22C3 and 28-8 to epitopes within the extra-
cellular domain). Furthermore, a number of associated
IHC protocols have been developed, relying on differing
antigen retrieval conditions and staining platforms in
particular. These differences are likely to generate differ-
ent staining patterns [22, 28, 55]. Tissue fixation, hand-
ling, processing, and timing of sample collection in
relation to current disease and treatment stage may also
influence assay outcomes. For these and other reasons,
the reliability of some data reported on PD-L1 expres-
sion has been difficult to assess, and highlights the need
for standardized use of well-validated PD-L1 assays for
the detection and scoring of PD-L1 in patient tumor
samples. A recent comparative study featuring the VEN-
TANA PD-L1 (SP263) Assay, showed a high analytical
correlation between the three different commercially
available PD-L1 assays (Dako 28.8, Dako 22C3 and
VENTANA SP263) [51].
The heterogeneity of PD-L1 expression also poses a
challenge for pathologists [28, 29]. Unlike other bio-
markers in NSCLC, PD-L1 protein expression does not
give a binary signal, instead, it presents as a continuum
of expression including absent, low, medium, and high
levels, and also varies between tumor cells [55]; some tu-
mors classified as PD-L1 low/negative at the biopsy site
may be PD-L1 high at a different location. The creation
of a binary positive or negative result for PD-L1 status is
achieved using a staining cut-off. This can mean that the
probability of response to anti-PD-1/PD-L1 treatment
differs very little in patients with PD-L1 low/negative tu-
mors just below the cut-off, and patients with PD-L1
high tumors just above the cut-off. The lower the stain-
ing cut-off, the greater the risk of misclassifying patients
in terms of probability of response [55]. These and other
concerns are currently being evaluated in ongoing clin-
ical trials with durvalumab monotherapy and combin-
ation therapies.
This analysis demonstrated the reliability of the PD-L1
(SP263) assay to determine the PD-L1 expression of
NSCLC and HNSCC tumor samples obtained in a clin-
ical setting based on a ≥25 % cut-off value for positively
stained tumor cells. Preliminary data from retrospective
analyses of tumor samples obtained from a clinical trial
of the anti-PD-L1 agent durvalumab, demonstrated that
PD-L1 high expression, identified by the PD-L1 (SP263)
assay and scoring algorithm, was a useful predictor of
treatment response [1].
Conclusions
The VENTANA PD-L1 (SP263) Assay met all of the pre-
defined acceptance criteria (according to its proposed
intended use as a clinical diagnostic test), showing ana-
lytical specificity, sensitivity, robustness and precision,
and obtaining the required performance scores for day-
to-day, site-to site and observer-to-observer repeatability
and reproducibility, confirming its reliability for staining
of FFPE NSCLC and HNSCC samples across different
testing environments.
The PD-L1 (SP263) assay is currently in use in on-
going clinical trials of durvalumab, as monotherapy and
in combination with tremelimumab, as part of a com-
prehensive clinical development program in NSCLC and
HNSCC. These studies support the use of the PD-L1
(SP263) assay for testing on clinical samples and form
the basis for confirming clinical utility.
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